<?xml version="1.0" encoding="UTF-8"?>
<p id="Par40">Antiviral drugs, such as remdesivir, lopinavir/ritonavir, and ribavirin, are also being administered in patients with more severe COVID-19 due to their potential benefit in viral RNA synthesis inhibition, diminishing RNA translation and viral exocytosis in host cells. In a cohort of 61 patients who received remdesivir therapy, 12% of the patients evolved with hypotension, being one of the most common serious adverse event, particularly in patients undergoing invasive ventilation. The improvement in oxygen support status was observed in 68% of the patients in the remdesivir group [
 <xref ref-type="bibr" rid="CR28">28</xref>].
</p>
